RS-601 

RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

RS-601 (1-10 mg/kg) clearly inhibits the bronchoconstriction induced by intravenous administration of U-46619 and LTD4 in a dose-dependent fashion in guinea pigs. RS-1452 (10 mg/kg) significantly inhibits U-46619-induced bronchoconstriction, respectively. RS-601 significantly inhibits the late-phase response and LPS-induced AHR at a dose of 10 mg/kg, but does not affect biphasic bronchial responses. RS-601 (3 and 10 mg/kg) also clearly inhibits the AHR^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

511.48

C₂₂H₂₃F₆NO₄S

207987-59-5

O=C(O)CCCC1=CC=C(C(NS(=O)(C2=CC=C(F)C=C2)=O)CCCC(F)(F)C(F)(F)F)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yamada T, et al. Effects of RS-601, a novel leukotriene D(4)/thromboxane A(2) dual receptor antagonist, on asthmatic responses in guinea pigs. Pharmacology. 2003 Sep;69(1):51-8.  [Content Brief]